UY31996A - Nuevos derivados de triazolo[4,3-a]piridina, y sus nuevos usos como inhibidores de met - Google Patents

Nuevos derivados de triazolo[4,3-a]piridina, y sus nuevos usos como inhibidores de met

Info

Publication number
UY31996A
UY31996A UY0001031996A UY31996A UY31996A UY 31996 A UY31996 A UY 31996A UY 0001031996 A UY0001031996 A UY 0001031996A UY 31996 A UY31996 A UY 31996A UY 31996 A UY31996 A UY 31996A
Authority
UY
Uruguay
Prior art keywords
new
triazolo
met inhibitors
piridina
derivatives
Prior art date
Application number
UY0001031996A
Other languages
English (en)
Inventor
Eric Bacque
Dominique Damour
Conception Nemecek
Sylvie Wentzler
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41550767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31996(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0804084A external-priority patent/FR2933980B1/fr
Priority claimed from FR0900245A external-priority patent/FR2941229B1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY31996A publication Critical patent/UY31996A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a los nuevos derivados de triazolo[4,3-a]piridina de fórmula (I), estando estos productos en todas las formas isómeras y las sales, donde los radicales, sustituyentes y subíndices son tales como se especifican en la Memoria Descriptiva y en las Reivindicaciones, que presentan actividad anticancerosa, mediante la modulación de la actividad de proteínas, en particular, de quinasas. La invención se refiere también a procedimiento de preparación, composiciones farmacéuticas y a su uso como medicamentos principalmente como inhibidores MET. Se divulgan como productos industriales nuevos, los intermedios de síntesis.
UY0001031996A 2008-07-18 2009-07-17 Nuevos derivados de triazolo[4,3-a]piridina, y sus nuevos usos como inhibidores de met UY31996A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0804084A FR2933980B1 (fr) 2008-07-18 2008-07-18 Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
FR0900245A FR2941229B1 (fr) 2009-01-21 2009-01-21 Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met

Publications (1)

Publication Number Publication Date
UY31996A true UY31996A (es) 2010-02-26

Family

ID=41550767

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031996A UY31996A (es) 2008-07-18 2009-07-17 Nuevos derivados de triazolo[4,3-a]piridina, y sus nuevos usos como inhibidores de met

Country Status (19)

Country Link
US (1) US20110263594A1 (es)
EP (1) EP2310366A2 (es)
JP (1) JP2011528337A (es)
KR (1) KR20110039558A (es)
CN (1) CN102159543A (es)
AR (1) AR072819A1 (es)
AU (1) AU2009272516A1 (es)
BR (1) BRPI0916464A2 (es)
CA (1) CA2730959A1 (es)
CL (1) CL2011000119A1 (es)
CO (1) CO6331463A2 (es)
EA (1) EA201170222A1 (es)
IL (1) IL210688A0 (es)
MA (1) MA32570B1 (es)
MX (1) MX2011000671A (es)
PE (1) PE20110560A1 (es)
TW (1) TW201008938A (es)
UY (1) UY31996A (es)
WO (1) WO2010007316A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
CN102762101B (zh) 2010-02-18 2014-09-17 高点制药有限责任公司 取代的稠合咪唑衍生物、药物组合物及其使用方法
FR2966151B1 (fr) * 2010-10-14 2012-11-09 Sanofi Aventis Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met
JP5808826B2 (ja) * 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
JP6355719B2 (ja) * 2013-05-10 2018-07-11 ジエンス ハンセン ファーマセウティカル カンパニー リミテッド ［１，２，４］トリアゾール［４，３−ａ］ピリジン誘導体、その製造方法またはその医薬応用
CA2914040A1 (en) * 2013-06-03 2014-12-11 Bayer Pharma Aktiengesellschaft Triazolopyridines as thrombin inhibitors for the treatment of thromboembolic diseases
GB201321742D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
CN106489962B (zh) * 2016-10-20 2019-02-22 贵州大学 一种[1,2,4]三唑[4,3-a]吡啶类含硫化合物在制备杀虫剂中的应用
JP7414282B2 (ja) 2017-12-07 2024-01-16 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｎｓｄファミリー阻害物質及びそれによる治療の方法
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2857371A (en) * 1954-09-10 1958-10-21 Eastman Kodak Co Benzothiazole azo diphenylamine compounds
AU548426B2 (en) * 1980-08-27 1985-12-12 Glaxo Group Limited 3-amino-(1,2,4)-triazoles
FR2601952B1 (fr) * 1986-07-23 1988-11-25 Carpibem Nouveaux derives amino alkyl thio de triazolopyridine ou triazoloquinoline, leurs procedes de preparation, medicaments les contenant, utiles notamment comme antalgiques
US7008748B1 (en) * 2004-09-07 2006-03-07 Eastman Kodak Company Silver salt-toner co-precipitates and imaging materials
ME02736B (me) * 2005-12-21 2017-10-20 Janssen Pharmaceutica Nv Triazolopiridazini kao modulatori tirozin kinaze
WO2008092891A1 (en) * 2007-02-01 2008-08-07 Glaxo Group Limited 1-oxa-3-azaspiro(4.5)decan-2-one derivatives for the treatment of eating disorders
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.

Also Published As

Publication number Publication date
CN102159543A (zh) 2011-08-17
EP2310366A2 (fr) 2011-04-20
TW201008938A (en) 2010-03-01
AU2009272516A1 (en) 2010-01-21
WO2010007316A2 (fr) 2010-01-21
AR072819A1 (es) 2010-09-22
BRPI0916464A2 (pt) 2018-06-12
PE20110560A1 (es) 2011-08-29
KR20110039558A (ko) 2011-04-19
JP2011528337A (ja) 2011-11-17
WO2010007316A3 (fr) 2010-04-29
US20110263594A1 (en) 2011-10-27
MA32570B1 (fr) 2011-08-01
CL2011000119A1 (es) 2011-06-17
CA2730959A1 (fr) 2010-01-21
MX2011000671A (es) 2011-04-11
EA201170222A1 (ru) 2011-08-30
CO6331463A2 (es) 2011-10-20
IL210688A0 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
UY31996A (es) Nuevos derivados de triazolo[4,3-a]piridina, y sus nuevos usos como inhibidores de met
UY31997A (es) Nuevos derivados de imidazo[1,2-a]piridina, y sus nuevos usos como inhibidores de met.
UY31998A (es) Nuevos derivados de imidazo[1,2-a]pirimidina, y sus nuevos usos como inhibidores de met
DOP2010000242A (es) Pirrolo[2,3-d]piridinas y usos de las mismas como inhibidores de cinasa de tirosina
UY30859A1 (es) Nuevos derivados de 2-anilino-4-heteroarilpirimidinas , su preparacion, como medicamentos, composiciones farmacéuticas y especialmente como inhibidores de ikk
CU20130129A7 (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA
UY29549A1 (es) Nuevos derivados del fluoreno, composiciones que los contienen y su utilización
UY29038A1 (es) Nuevos derivados de urea cíclicos sustituidos, su preparación y su uso farmacéutico como inhibidores de quinasa
CO6450612A2 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
UY31730A (es) Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridinas, su preparación y su aplicación en terapéutica.
BR112013018515A2 (pt) derivados de pirrol tricíclico, processo para preparação e seu uso como inibidores da quinase
UY30857A1 (es) Nuevos derivados de n,n'-2,4 dianilinopirimidinas, su preparacion, como medicamentos, composiciones farmacéuticas y especialmente como inhibidores de ikk
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
ECSP14013215A (es) Compuestos novedosos
UY31367A1 (es) Derivados de nicotinamida, su preparacion y su aplicacion en terapeutica
UY30858A1 (es) Nuevos derivados de fenil-(4-fenil-pirimidin-2-il)- aminas, su preparacion, como medicamentos, composiciones farmacéuticas y especialmente como inhibidores de ikk
BR112012029647A2 (pt) novos derivados de pirimidinas
UY30856A1 (es) Nuevos derivados de 2,4 dianilinopirimidinas, su preparacion, como medicamentos, composiciones farmacéuticas y principalmente como inhibidores de ikk
UY31651A1 (es) Nuevos derivados de fluoroglicósidos aromáticos, medicamentos que comprenden estos compuestos y uso de los mismos.
EA201491376A1 (ru) Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы
CR20140218A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas iii
UY32755A (es) Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt (pkb).
UY31278A1 (es) Nuevos derivados de n, n??-2,4-dianilinopirimidinas, su preparacion, como medicamentos, composiciones farmacéuticas y especialmente como inhibidores de ikk
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
UY32753A (es) NUEVOS DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA, SU PREPARACIÓN Y SU UTILIZACIÓN EN FARMACÉUTICA

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140519